Article
Mutation-Specific CRISPR Targeting with SaCas9 and AsCas12a Restores Therapeutic Sensitivity in Treatment-Resistant Melanoma.
The CRISPR journal - 1 Dec 2024
Sansbury Brett M, Masciarelli Sophia B, Kaouser Salma, Tharp Olivia M, Banas Kelly H, Kmiec Eric B
Abstract excerpt
Background: Melanoma remains one of the most challenging cancers to treat effectively with drug resistant remaining a constant concern, primarily with activating BRAF mutations. Mutations in the BRAF gene appear in approximately 50% of patients, 90% of which are V600E. Two frontline BRAF inhibitors (BRAFi), vemurafenib and dabrafenib, are frequently used to treat unresectable or metastatic BRAF V600E melanoma....
Topics
- Melanoma
- Humans
- CRISPR-Cas Systems
- Drug Resistance, Neoplasm
- Gene Editing
- Proto-Oncogene Proteins B-raf
- Mutation
- Cell Line, Tumor
- Vemurafenib
- CRISPR-Associated Protein 9